Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight Business Research LLP | PRODUCT CODE: 1147341

Cover Image

PUBLISHER: DelveInsight Business Research LLP | PRODUCT CODE: 1147341

Glioblastoma Multiforme (GBM) - Epidemiology Forecast - 2032

Published: Pre-Order
PAGES: 326 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 4750
PDF (2-3 user license)
USD 7125
PDF (Site License)
USD 9500
PDF (Global License)
USD 14250

Add to Cart

DelveInsight's " Glioblastoma Multiforme - Epidemiology Forecast- 2032" report delivers an in-depth understanding of the GBM, historical and forecasted epidemiology trends in the United States, the EU-4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Geography Covered:

  • The United States
  • The EU-4 (Germany, France, Italy, and Spain), and the United Kingdom
  • Japan

Study Period: 2019-2032.

Glioblastoma Multiforme Disease Understanding and Treatment Algorithm

Glioblastoma Multiforme Overview

GBM is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. GBM is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced process such as speech and emotions.

The exact underlying cause of GBM is unknown. Some cases may develop from existing, low-grade astrocytomas (malignant transformation) or they may occur without any evidence of a previous tumor (de novo).

GBM Diagnosis

The diagnosis of GBM includes neurological exams (This exam tests vision, hearing, speech, strength, sensation, balance, coordination, reflexes and the ability to think and remember), Angiograms, Magnetic resonance imaging (MRI) and computerized Tomography (CT), surgical biopsy and others.

GBM Treatment

Treatment for GBM usually includes a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Chemotherapy includes Carmustine (BCNU), Lomustine (CCNU), or Gleostine (Generic), Gliadel wafer (biodegradable discs infused with BCNU), Temozolomide (Temodar) Cisplatin, Carboplatin, Etoposide and Irinotecan. They may be given as a single agent or in combination i.e. PCV (Procarbazine, CCNU, and Vincristine), Carboplatin/ Etoposide. The drugs most commonly used to treat brain tumors are temozolomide (Temodar) and bevacizumab (Avastin).

Glioblastoma Multiforme Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of GBM, Gender-specific Diagnosed Incidence of GBM, Type-specific Diagnosed Incidence of GBM, Age-specific Diagnosed Incidence of GBM, Diagnosed Incident Population based on Primary Site of GBM, and Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the 7MM market covering the United States, EU-4 countries (Germany, France, Italy, and Spain), the United Kingdom and Japan from 2019 to 2032.

Key Findings:

This section provides glimpse of the GBM epidemiology in the 7MM.

Country Wise- Glioblastoma Multiforme Epidemiology

  • The epidemiology segment also provides the GBM epidemiology data and findings across the United States, the EU 4 (Germany, France, Italy, Spain), the United Kingdom) and Japan.
  • The Total Diagnosed Incident Population of Glioblastoma Multiforme in the 7MM comprised of 32,546 cases in 2021 and are projected to increase during the forecast period.
  • The Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States, in which maximum cases were recorded in male population 7,705 in 2021, as compared to female population.
  • Among the EU-4, and the UK countries, Germany accounted for the highest number of GBM cases, followed by France, whereas Spain accounted for the lowest cases in 2021.
  • In Japan, the Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan was of two types in which maximum cases were recorded of Primary GBM/ IDH-wild Type 2,541 in 2021 and is anticipated to rise during the forecast period.

Scope of the Report:

  • The report covers the descriptive overview of GBM, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the GBM epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for GBM are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of GBM market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM GBM market.

Report Highlights:

  • In the coming years, GBM market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence GBM R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • As per DelveInsight's analysis of GBM types Primary GBM/ IDH-wild Type and Secondary GBM/ IDH Mutant.

GBM Report Insights

  • Patient Population
  • Therapeutic Approaches
  • 7MM Coverage
  • GBM Epidemiology Segmentation

Key Questions

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of GBM?
  • What is the historical GBM patient pool in the United States, the EU-4 (Germany, France, Italy, and Spain), the UK and Japan?
  • What would be the forecasted patient pool of GBM at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to GBM?
  • Out of the above-mentioned countries, which country would have the highest incident population of GBM during the study period (2019-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the GBM.
  • To understand the future market competition in the GBM market and Insightful review of the SWOT analysis of GBM.
  • Organize sales and marketing efforts by identifying the best opportunities for GBM in the US, EU 4 (Germany, Spain, Italy, France) the United Kingdom, and Japan.
  • The GBM Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.
Product Code: DIEI0292

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology Methodology

5. Disease Background And Overview

  • 5.1. Introduction
  • 5.2. Classification of Glioblastoma Multiforme
  • 5.3. Glioblastoma Types
    • 5.3.1. Astrocytomas
    • 5.3.2. Ependymomas
    • 5.3.3. Oligodendrogliomas
    • 5.3.4. Mixed gliomas
    • 5.3.5. Optic pathway gliomas
  • 5.4. Symptoms
  • 5.5. Pathophysiology
    • 5.5.1. Macroscopic and Histological Features of GBM
    • 5.5.2. Genetic and Molecular Pathogenesis
  • 5.6. Inheritance of Glioblastoma Multiforme
    • 5.6.1. Genetic Variations of Glioblastoma Multiforme
    • 5.6.2. Isocitrate dehydrogenase mutations
    • 5.6.3. O (6)-Methylguanine-DNA methyltransferase promoter methylation
    • 5.6.4. Telomerase reverse transcriptase promoter mutations
    • 5.6.5. Epidermal growth factor receptor aberrations
    • 5.6.6. PTEN alterations
    • 5.6.7. Other novel genetic aberrations
  • 5.7. Molecular Classification
    • 5.7.1. Specific Molecular Biomarkers
  • 5.8. Diagnosis of Glioblastoma Multiforme
    • 5.8.1. Neurological Exams
    • 5.8.2. Angiograms
    • 5.8.3. Magnetic resonance imaging (MRI) and computerized Tomography (CT)
    • 5.8.4. Perfusion MRI
    • 5.8.5. MR spectroscopy
    • 5.8.6. Histological Diagnosis
    • 5.8.7. Surgical Biopsy
  • 5.9. Glioblastoma in Nut Shell
  • 6.10. The United States
    • 6.10.1. Total Incident Cases of GBM in the United States
    • 6.10.2. Gender-specific Incidence Cases of GBM in the United States
    • 6.10.3. Type-specific Incidence Cases of GBM in the United States
    • 6.10.4. Age-specific Incidence Cases of GBM in the United States
    • 6.10.5. Incident Cases based on Primary Site of GBM in the United States
    • 6.10.6. Incident Cases based on Histologic Classification of GBM Tumor in the United States
  • 6.11. EU 4 and UK
    • 6.11.1. Total Incident Cases of GBM in the EU-4 and the UK
    • 6.11.2. Gender-specific Incidence Cases of GBM in the EU-4 and the UK
    • 6.11.3. Type-specific Incidence Cases of GBM in the EU-4 and the UK
    • 6.11.4. Age-specific Incidence Cases of GBM in the EU-4 and the UK
    • 6.11.5. Incident Cases Based on Primary Site of GBM in the EU-4 and the UK
    • 6.11.6. Incident Cases based on Histologic Classification of GBM Tumor in the EU-4 and the UK
  • 6.12. Japan
    • 6.12.1. Total Incident Cases of GBM in Japan
    • 6.12.2. Gender-specific Incidence Cases of GBM in Japan
    • 6.12.3. Type-specific Incidence Cases of GBM in Japan
    • 6.12.4. Age-specific Incidence Cases of GBM in Japan
    • 6.12.5. Incident Cases based on Primary Site of GBM in Japan
    • 6.12.6. Incident Cases based on Histologic Classification of GBM in Japan

7. Appendix

  • 7.1. Bibliography
  • 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

Product Code: DIEI0292

List of Tables

  • Table 1: Summary of GBM Market, and Epidemiology (2019-2032)
  • Table 2: Total Incident Patient Population of GBM in the 7MM (2019-2032)
  • Table 3: Total Incident Population of GBM in the US (2019-2032)
  • Table 4: Gender-specific Incidence Cases of GBM in the US (2019-2032)
  • Table 5: Type-specific Incidence Cases of GBM in the US (2019-2032)
  • Table 6: Age-specific Incidence Cases of GBM in the US (2019-2032)
  • Table 7: Incident Cases Based on Primary Site of GBM Tumor in the US (2019-2032)
  • Table 8: Incident Cases Based on Histologic Classification of GBM Tumor in the US (2019-2032)
  • Table 9: Total Incident Cases of GBM in the EU-4 and the UK (2019-2032)
  • Table 10: Gender-specific Incidence Cases of GBM in the EU-4 and the UK (2019-2032)
  • Table 11: Type-specific Incidence Cases of GBM in the EU-4 and the UK (2019-2032)
  • Table 12: Age-specific Incidence Cases of GBM in the EU-4 and the UK (2019-2032)
  • Table 13: Incident Cases Based on Primary Site of GBM Tumor in the EU-4 and the UK (2019-2032)
  • Table 14: Incidence Cases Based on Histologic Classification of GBM Tumor in the EU-4 and the UK (2019-2032)
  • Table 15: Total Incident Cases of GBM in Japan (2019-2032)
  • Table 16: Gender-specific Incidence Cases of GBM in Japan (2019-2032)
  • Table 17: Type-specific Incidence Cases of GBM in Japan (2019-2032)
  • Table 18: Age-specific Incidence Cases of GBM in Japan (2019-2032)
  • Table 19: Incident Cases Based on Primary Site of GBM Tumor in Japan (2019-2032)
  • Table 20: Incident Cases Based on Histologic Classification of GBM Tumor in Japan (2019-2032)

List of Figures

Figure1: Summary of GBM Market, and Epidemiology (2019-2032)

  • Figure 2: Total Incident Population of GBM in the US (2019-2032)
  • Figure 3: Gender-specific Incidence Cases of GBM in the US (2019-2032)
  • Figure 4 Type-specific Incidence Cases of GBM in the US (2019-2032)
  • Figure 5: Age-specific Incidence Cases of GBM in the US (2019-2032)
  • Figure 6: Incident Cases Based on Primary Site of GBM Tumor in the US (2019-2032)
  • Figure 7: Incident Cases Based on Histologic Classification of GBM Tumor in the US (2019-2032)
  • Figure 8: Total Incident Cases of GBM in the EU-4 and the UK (2019-2032)
  • Figure 9: Gender-specific Incidence Cases of GBM in the EU-4 and the UK (2019-2032)
  • Figure 10: Type-specific Incidence Cases of GBM in the EU-4 and the UK (2019-2032)
  • Figure 11: Age-specific Incidence Cases of GBM in the EU-4 and the UK (2019-2032)
  • Figure 12: Incident Cases Based on Primary Site of GBM Tumor in the EU-4 and the UK (2019-2032)
  • Figure 13: Incidence Cases Based on Histologic Classification of GBM Tumor in the EU-4 and the UK (2019-2032)
  • Figure 14: Total Incident Cases of GBM in Japan (2019-2032)
  • Figure 15: Gender-specific Incidence Cases of GBM in Japan (2019-2032)
  • Figure 16: Type-specific Incidence Cases of GBM in Japan (2019-2032)
  • Figure 17: Age-specific Incidence Cases of GBM in Japan (2019-2032)
  • Figure 18: Incident Cases Based on Primary Site of GBM in Japan (2019-2032)
  • Figure 19: Incident Cases Based on Histologic Classification of GBM in Japan (2019-2032)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!